Full OptIMMize-1 results show high skin clearance rates with risankizumab in children and teens with psoriasis, sustained through 52 weeks.
|Articles|July 1, 2010
Birthmarks in newborns can signal later problems
Vascular birthmarks are very common in newborns, and some varieties affect up to 50% of babies.
Advertisement
Vascular birthmarks are very common in newborns, and some varieties affect up to 50% of babies. The challenge for dermatologists can be the early diagnosis and the ability to distinguish the subtle differences between a banal birthmark and one that calls for quick action.
Advertisement
Related to this article
Emily Becker, MD, discusses the role of AhR agonists, skin barrier function, and steroid-free treatment options for pediatric atopic dermatitis.
A meta-analysis of 52 studies links NO2, SO2, and particulate matter to more pediatric atopic dermatitis visits and higher prevalence.
Christina Boull, MD, explains how pediatricians can recognize dermatologic conditions in darker skin tones and address pigment changes and treatment gaps.
Christina Boull, MD, shares recommendations for infant skin care, including choosing gentle cleansers, avoiding irritants, and supporting the skin barrier.
Topical botanical Cinainu earned FDA Breakthrough Therapy status for AA in patients aged 2+, supported by phase 2/3 RAAINBOW data in children.
Real-world claims show dupilumab was tied to a 33%-52% lower risk of atopic march progression vs systemic corticosteroids in children with AD.
Once-daily roflumilast cream 0.05% was well tolerated in infants 3 to <24 months with AD, with 34.4% reaching vIGA-AD success at week 4.
Advertisement
Advertisement
Trending on Contemporary Pediatrics
1
How pediatricians can reframe vaccine conversations
2
FDA investigates malignancy risk with SMA gene therapy Zolgensma
3
Distance to surgery linked to complications, longer stays in children
4
Risankizumab shows 52-week efficacy in pediatric psoriasis trial
5